Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 21 studies | 33% ± 19% | |
basal cell | 18 studies | 42% ± 18% | |
smooth muscle cell | 15 studies | 31% ± 14% | |
pericyte | 12 studies | 25% ± 13% | |
connective tissue cell | 9 studies | 28% ± 15% | |
myofibroblast cell | 8 studies | 35% ± 13% | |
goblet cell | 8 studies | 37% ± 13% | |
secretory cell | 7 studies | 36% ± 15% | |
endothelial cell | 7 studies | 27% ± 12% | |
epithelial cell | 7 studies | 39% ± 12% | |
cardiac muscle cell | 7 studies | 80% ± 13% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 35% ± 12% | |
adipocyte | 4 studies | 24% ± 7% | |
respiratory goblet cell | 3 studies | 27% ± 9% | |
squamous epithelial cell | 3 studies | 41% ± 22% | |
extravillous trophoblast | 3 studies | 84% ± 5% | |
placental villous trophoblast | 3 studies | 37% ± 12% | |
abnormal cell | 3 studies | 25% ± 7% | |
keratinocyte | 3 studies | 32% ± 9% | |
myoepithelial cell | 3 studies | 61% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 4730.70 | 966 / 966 | 99% | 67.01 | 520 / 527 |
esophagus | 100% | 3593.35 | 1440 / 1445 | 96% | 47.57 | 175 / 183 |
bladder | 100% | 4807.33 | 21 / 21 | 95% | 57.93 | 479 / 504 |
ovary | 100% | 33284.75 | 180 / 180 | 94% | 32.17 | 405 / 430 |
stomach | 98% | 4948.56 | 353 / 359 | 96% | 56.43 | 274 / 286 |
uterus | 100% | 6044.80 | 170 / 170 | 93% | 46.16 | 427 / 459 |
prostate | 100% | 6358.03 | 244 / 245 | 92% | 30.13 | 462 / 502 |
breast | 99% | 4746.78 | 455 / 459 | 90% | 43.38 | 1004 / 1118 |
skin | 100% | 4567.30 | 1806 / 1809 | 75% | 22.78 | 354 / 472 |
kidney | 87% | 2126.33 | 77 / 89 | 76% | 23.44 | 689 / 901 |
lung | 70% | 1045.07 | 403 / 578 | 86% | 34.29 | 992 / 1155 |
thymus | 100% | 3057.92 | 650 / 653 | 51% | 9.63 | 311 / 605 |
adrenal gland | 100% | 4554.19 | 257 / 258 | 50% | 12.47 | 115 / 230 |
pancreas | 7% | 76.46 | 23 / 328 | 96% | 66.79 | 170 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 63.79 | 1 / 1 |
heart | 100% | 34504.91 | 858 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4052.85 | 1329 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 3969.35 | 1197 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 27.80 | 42 / 45 |
muscle | 89% | 2020.25 | 716 / 803 | 0% | 0 | 0 / 0 |
spleen | 78% | 1311.22 | 187 / 241 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 69% | 14.25 | 55 / 80 |
liver | 30% | 536.86 | 68 / 226 | 23% | 4.37 | 94 / 406 |
brain | 21% | 331.27 | 556 / 2642 | 13% | 2.28 | 95 / 705 |
lymph node | 0% | 0 | 0 / 0 | 10% | 1.13 | 3 / 29 |
peripheral blood | 1% | 12.61 | 9 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0055015 | Biological process | ventricular cardiac muscle cell development |
GO_0070885 | Biological process | negative regulation of calcineurin-NFAT signaling cascade |
GO_0060347 | Biological process | heart trabecula formation |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0009725 | Biological process | response to hormone |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0055014 | Biological process | atrial cardiac muscle cell development |
GO_0030018 | Cellular component | Z disc |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005925 | Cellular component | focal adhesion |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0043425 | Molecular function | bHLH transcription factor binding |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FHL2 |
Protein name | Four and a half LIM domains protein 2 (FHL-2) (LIM domain protein DRAL) (Skeletal muscle LIM-protein 3) (SLIM-3) Four-and-a-half LIM domains 2 Uncharacterized protein FHL2 FHL2 protein (Four and a half LIM domains 2) (HCG28013, isoform CRA_a) Four and a half LIM domains 2 |
Synonyms | SLIM3 DRAL hCG_28013 |
Description | FUNCTION: May function as a molecular transmitter linking various signaling pathways to transcriptional regulation. Negatively regulates the transcriptional repressor E4F1 and may function in cell growth. Inhibits the transcriptional activity of FOXO1 and its apoptotic function by enhancing the interaction of FOXO1 with SIRT1 and FOXO1 deacetylation. Negatively regulates the calcineurin/NFAT signaling pathway in cardiomyocytes . . |
Accessions | ENST00000322142.13 [Q14192-1] C9J3S8 ENST00000607522.1 Q14192 ENST00000393353.7 [Q14192-1] ENST00000408995.5 [Q14192-1] ENST00000358129.8 [Q14192-2] U3KQT4 F8WDA8 ENST00000447958.1 Q53T40 Q53QP3 ENST00000344213.9 [Q14192-1] ENST00000452732.1 ENST00000409177.6 [Q14192-1] Q6I9R8 ENST00000530340.6 [Q14192-1] ENST00000393352.7 [Q14192-1] ENST00000409807.5 [Q14192-1] I0CE67 |